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Background: The autosomal dominant spinocerebellar ataxias (SCAs) confine a group of rare and heterogeneous
disorders, which present with progressive ataxia and numerous other features e.g. peripheral neuropathy, macular
degeneration and cognitive impairment, and a subset of these disorders is caused by CAG-repeat expansions in
their respective genes. The diagnosing of the SCAs is often difficult due to the phenotypic overlap among several
of the subtypes and with other neurodegenerative disorders e.g. Huntington’s disease.
Case presentation: We report a family in which the proband had rapidly progressing cognitive decline and only
subtle cerebellar symptoms from age 42. Sequencing of the TATA-box binding protein gene revealed a modest
elongation of the CAG/CAA-repeat of only two repeats above the non-pathogenic threshold of 41, confirming a
diagnosis of SCA17. Normally, repeats within this range show reduced penetrance and result in a milder disease
course with slower progression and later age of onset. Thus, this case presented with an unusual phenotype.
Conclusions: The current case highlights the diagnostic challenge of neurodegenerative disorders and the need
for a thorough clinical and paraclinical examination of patients presenting with rapid cognitive decline to make a
precise diagnosis on which further genetic counseling and initiation of treatment modalities can be based.
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Autosomal dominant spinocerebellar ataxias (SCAs)
confine a group of rare and heterogeneous hereditary
disorders which present with progressive ataxia and nu-
merous other features e.g. peripheral neuropathy, macu-
lar degeneration and cognitive impairment [1]. 32
subtypes of the autosomal dominantly inherited ataxias
are known, and 8 of these (SCA1, 2, 3, 6, 7, 12, 17 and
Dentato-rubro-pallido-Luysian atrophy (DRPLA)) are
caused by CAG repeat expansions in the respective* Correspondence: troelsn@sund.ku.dk
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reproduction in any medium, provided the orgenes underlying disease [1,2]. The expanded CAG re-
peat results in an elongated polyglutamine tract that
interferes with normal protein function [1,3]. SCA17, a
member of the group of polyglutaminopathies, is caused
by a CAG/CAA repeat expansion in the gene encoding
the TATA-box binding protein (TBP), which is a general
transcription factor crucial for normal cellular function
and development [4]. The normal range of glutamine
stretches in TBP is 25–41. Stretches of 49 or more gluta-
mines are disease causing with full penetrance, whereas
stretches of 42–48 glutamines are associated with
reduced penetrance [5]. The clinical diagnosing of
SCA17 patients is complex. Typically ataxic gait and
dysarthria are the most prominent signs, but other fea-
tures include personality changes, depression, cognitive
impairment and basal ganglia dysfunction. Hence,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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syndrome. All symptoms can be present at different
times and to a varying degree during the course of dis-
ease, and because there is a significant phenotypic over-
lap with other neurodegenerative disorders such as
Huntington’s disease (HD) as well as with other SCAs,
diagnosis based on the clinical presentation remains a
considerable challenge [6]. The age of onset in SCA17 is
highly variable (between 3 and 55 years), and although
there is some correlation between age of onset and the
number of CAG/CAA repeats it seems to be less pro-
nounced compared to other polyglutamine disorders e.g.
HD. Similarly, anticipation is infrequently reported in
SCA17 families due to an interruption of the CAG re-
peat sequence by a CAACAGCAA sequence that seems
to stabilize the repeat during replication [7,8]. A milder
phenotype with later age of onset and slower disease
progression seems to be associated with repeat lengths
in the shorter end of the reduced penetrance range (42–
44 CAG/CAA repeats) while a more severe and rapidly
progressing phenotype is seen in patients with longer
repeats [4,8-10]. Here we report on a family in which
the proband shows only very modest cerebellar symp-
toms consisting of mild ataxia and dysarthria. Interest-
ingly, he has severe cognitive impairment with rapid
progression although the CAG/CAA repeat in the TBP
gene is expanded by only two repeats above the non-
pathogenic threshold of 41 repeats.
Case presentation
Family history
No other family member was reported to have symp-
toms like the proband (Figure 1, III-5); however, the
mother (Figure 1, II-4) was diagnosed with multiple
sclerosis since the age of 40 with motor deficits and dif-
ficulties in coordination as the first signs of disease andFigure 1 Pedigree of the SCA17 family. Individuals marked with solid bl
manifestations of neurological disorders. Individuals marked with gray shad
been confirmed on the molecular level. The proband is marked by an arroonly later developed cognitive impairment. She is now
severely disabled, wheel chair bound and fully dependent
on daily caregivers at age 74. The mother’s brother, living
abroad, (Figure 1, II-2) was diagnosed with Parkinson’s
disease and the maternal grandfather (Figure 1, I-2) was
reported to have died from Parkinson’s disease (Figure 1).
Clinical features
The proband (Figure 1, III-5) was referred to the hos-
pital at the age of 44. He had worked as a blacksmith
until two years before referral, when he was fired due to
reduced speed of working. At that time there were no
symptoms of cognitive impairment, neither by self
reporting nor was it reported by family members. How-
ever, over the following 1-1½ years his personality chan-
ged and, according to his wife, cognitive impairment
evolved rapidly. Furthermore, he also had mild deterior-
ation of motor capabilities and coordination of move-
ments that accelerated 6 months prior to referral. Upon
initial clinical examination he was disorientated in time
and place. He denied any symptoms, was easily distracti-
ble and presented head turning sign and severe word
finding difficulties. MMSE score was 14/30. He had hori-
zontal nystagmus, slightly interrupted saccades though
with normal initiation, amplitude and velocity, and
smooth pursuit of eye movements was impaired. Exam-
ination also revealed a fine postural tremor of his hands,
a finger tapping test with reduced speed and hand dys-
diadokokinesia. He had discrete lower limb ataxia along
with a mildly broad based gait, but no upper limb ataxia.
Tone was slightly increased in the right leg. Tendon
reflexes were brisk in the lower extremities, although the
ankle reflexes were absent, and plantar reflexes were
flexor. There were no involuntary movements or muscu-
lar weakness.ack have a molecular diagnosis of SCA17 accompanied by clinical
ing have a clinical diagnosis of a neurological disorder, which has not
w.
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Blood biochemistry was normal and cerebrospinal fluid
protein concentrations and cell counts were normal.
Aβ1-42, total-tau, phosphorylated tau-protein, p14-3-3,
and neuron specific enolase concentrations were within
the normal range and oligoclonal bands were absent.
Standard EEG was abnormal with 3–6 Hz activity over
the prefrontal and zygomatico temporal regions observed
few times in 2–3 s periodic patterns, but without focal or
paroxysmal changes.
Neuropsychology
As indicated by the MMSE score of 14/30, neuropsycho-
logical testing revealed moderate to severe impairment
of all cognitive domains and formal testing was difficult.
The proband’s attention was drifting and he had pro-
blems understanding questions and instructions. He oc-
casionally showed awareness of his difficulties, but did
not appear emotionally affected. In contrast, he was
smiling almost constantly. Testing showed executive
functions to be severely impaired and hardly any test
within this domain could be conducted. Episodic mem-
ory was affected to a degree where the proband was dis-
orientated in time. However, he was not severely
amnesic as he recognized 10/12 pictures among 30
(expected: 12/12) and he was also able to recall episodes
which had taken place a few days prior. Language func-
tions were impaired with anomia (inability to name
objects), alexia and agraphia. There were signs of acalcu-
lia, apraxia and visuospatial impairment (inability to
copy simple drawings or assemble simple block designs).
Altogether the test profile suggested bilateral cortical in-
volvement with both anterior and posterior cortical
areas being severely affected.Figure 2 Brain MRI and 18 F-FDG-PET-scan of the proband in the trans
(DWI) and a T2* weighted sequence. No focal lesions were observed; howe
(arrow heads). B: 18 F-FDG-PET-scan showing strikingly reduced metabolism
cerebellum.Imaging
I123-FP-CIT DAT SPECT was normal (not shown). Brain
MRI showed no focal lesions, but the cerebellar hemi-
spheres and vermis appeared atrophic (Figure 2A). The
MRI scan included a diffusion weighted sequence (DWI)
and a T2* weighted sequence. There was no sign of
restricted diffusion as may be seen in Creutzfeldt-Jakob
disease or excessive iron accumulation in the basal gan-
glia which may be suggestive of other causes of neurode-
generaton. 18 F-FDG-PET-scan showed strikingly reduced
metabolism in the cerebellum (Figure 2B) supporting the
cerebellar atrophy visualized by MRI, suggesting path-
ology localized to the cerebellum. Furthermore, slightly
decreased metabolism in the left caudate nucleus was
observed, although this finding could only be detected by
comparison to scans of normal control individuals with
subsequent statistical analyses using NeuroQ software
(Philips Healthcare).
Mutation analyses
The proband’s DNA was screened for mutations in the
genes known to cause SCA1, SCA2, SCA3 and SCA6.
Due to the phenotypic overlap with many of the polyglu-
tamine diseases analyses for HD and DRPLA were also
performed. All were normal. The length of the CAG/
CAA repeat in the gene causing SCA17, TBP, was deter-
mined by fragment analysis of a PCR product amplified
from patient DNA using primers 5’-ATG CCT TAT
GGC ACT GGA CTG-3’ and 5’-CTG CTG GGA CGT
TGA CTG CTG-3’. This revealed a modest expansion of
the CAG/CAA repeat of one allele and a CAG/CAA re-
peat within the normal range on the other allele (43 and
38 CAG/CAA repeats, respectively). After cloning of the
PCR products into the PCR2.1 vector (Invitrogen) directverse plane. A: The MRI scan included a diffusion weighted sequence
ver, the cerebellar hemispheres and vermis appeared atrophic
in the cerebellum suggesting pathology primarily localized to the
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From this it is evident that the patient suffers from
SCA17 with repeat structures similar to what has previ-
ously been described [4,8,9]. Subsequently, DNA from
the patient’s parents were analyzed and showed that the
patient’s father (Figure 1, II-5) had two normal alleles
of 37 and 38 CAG/CAA repeats, whereas his mother
(Figure 1, II-4) had alleles of 37 and 43 CAG/CAA repeats.
Discussion
Here we report on a patient who was referred to the
hospital due to rapid cognitive decline. Due to the severe
cognitive impairment and rapid progression, the patient
was initially suspected of Creutzfeldt-Jakob disease or a
paraneoplastic syndrome. Cerebellar symptoms were not
predominant in the clinical picture, but the MRI scan
revealed mild atrophy of the cerebellar hemispheres and
vermis, and reduced metabolism in the cerebellum
visualized by a FDG-PET scan supported the suspicion
that the diagnosis should be sought within the cerebellar
disorders. The family history revealed a high prevalence
of apparently different neurodegenerative disorders
based on clinical diagnoses. Considering the phenotypic
overlap of many neurodegenerative disorders, this family
history was suggestive of a dominantly inherited dis-
order. Molecular genetic analyses revealed that the pro-
band suffered from SCA17 and that he inherited the
disease causing mutation through the maternal line. Di-
verse phenotypes resembling both HD, Alzheimer’s dis-
ease and Parkinson’s disease have previously been
reported in patients with short expansions in the TBP
gene [10,11]. Hence, it is highly likely that the mother’s
and the mother’s brother’s diagnoses of multiple scler-
osis and Parkinson’s disease, respectively, are incorrect,
and that the neurological disorders described in this
family represent an example of the broad phenotypic
variation of SCA17. Unfortunately, only the proband
was available for clinical examination, and the family dis-
ease history is based solely on information provided by
the proband’s wife.
Cloning of the proband’s alleles of the TBP gene
showed only marginal expansion of the disease causing
CAG/CAA repeat with a length of 43. Considering that
alleles with repeat lengths of 42–48 have previously been
reported to cause disease with reduced penetrance [5]
and that repeat lengths in the shorter end of this range
usually cause mild disease progression [5,9,12,13], our
case is interesting because of the rapid deterioration
observed.Neuropathology has shown both cerebellar and basal
ganglia involvement in SCA17 [14,15], and dopaminergic
cell loss has been documented by reduced tracer uptake
with SPECT-I123 FP-CIT [14] and Fluoro-dopa PET
[16]. Such basal ganglia involvement has not been
reported to correlate with symptoms of parkinsonism
[17], but it has been suggested to be a function of the se-
verity of the disease with normal uptake of I123 FP-CIT
and Fluoro-dopa in pre-clinical stages [14]. Furthermore,
basal ganglia involvement has been suggested to be asso-
ciated with putaminal rim hyperintensity signal on T2
MRI in other cases [6,18,19], and voxel based morphom-
etry has indicated an increased involvement of basal
ganglia as the disease progresses [20]. The proband
exhibited a rapid and severe decline in cognitive func-
tion suggesting an advanced stage of disease, and in-
volvement of the basal ganglia would therefore not have
been surprising. However, only slightly decreased metab-
olism in the left caudate nucleus was observed by the
18 F-FDG-PET-scan and we did not see any involvement
of basal ganglia on MRI or SPECT-I123 FP-CIT, which
emphasizes the heterogeneity of phenotypic presentation
and pathology.
The current case emphasizes that diagnosing of neuro-
degenerative disorders remains a considerable challenge
due to the phenotypic overlap, and it shows that the
clinical manifestations and the disease course can be dif-
ferent from the classic description of the individual dis-
orders. SCA17 is a very rare disorder and the phenotypic
variation is therefore not fully described. Our case con-
tributes to a more detailed characterization of the highly
variable clinical picture seen in SCA17, and it highlights
the need for a careful clinical and paraclinical examin-
ation of patients displaying symptoms of early onset
neurodegeneration to enable precise diagnosing on
which further counseling and initiation of treatment mo-
dalities can be based.Conclusion
Here we report on a family with an only marginally
expanded CAG/CAA repeat in the TBP gene in which
the proband presents with severe and rapidly progres-
sing cognitive decline and only mild cerebellar symp-
toms. The set of symptoms should be considered when
diagnosing patients with rapidly progressing cognitive
decline.Consent
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